Bioventus Inc (BVS) - Total Liabilities
Based on the latest financial reports, Bioventus Inc (BVS) has total liabilities worth $416.27 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bioventus Inc - Total Liabilities Trend (2014–2025)
This chart illustrates how Bioventus Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Bioventus Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Bioventus Inc Competitors by Total Liabilities
The table below lists competitors of Bioventus Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nanjing Railway New Technology Co.Ltd.
SHE:301016
|
China | CN¥134.06 Million |
|
Kambi Group PLC Series B
IL:0EAW
|
UK | Skr33.48 Million |
|
Contrel Technology Co Ltd
TWO:8064
|
Taiwan | NT$2.14 Billion |
|
Abacus Group
AU:ABG
|
Australia | AU$1.05 Billion |
|
Shenzhen Jiawei Photovoltaic Lighting Co Ltd
SHE:300317
|
China | CN¥1.48 Billion |
|
Zhejiang Feida Environmental Science & Technology Co Ltd
SHG:600526
|
China | CN¥7.15 Billion |
|
Groupe CRIT SA
PA:CEN
|
France | €875.15 Million |
|
Northrim BanCorp Inc
NASDAQ:NRIM
|
USA | $3.02 Billion |
Liability Composition Analysis (2014–2025)
This chart breaks down Bioventus Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BVS asset base.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bioventus Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bioventus Inc (2014–2025)
The table below shows the annual total liabilities of Bioventus Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $455.11 Million | -16.09% |
| 2024-12-31 | $542.35 Million | -8.04% |
| 2023-12-31 | $589.79 Million | -38.59% |
| 2022-12-31 | $960.43 Million | +38.78% |
| 2021-12-31 | $692.07 Million | +97.56% |
| 2020-12-31 | $350.31 Million | +7.20% |
| 2019-12-31 | $326.79 Million | +9.86% |
| 2018-12-31 | $297.46 Million | +0.83% |
| 2015-12-31 | $295.01 Million | +16.64% |
| 2014-12-31 | $252.93 Million | -- |
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more